My Blog
Food

Post Holdings CEO returns after taking leave for cancer treatment

Post Holdings CEO returns after taking leave for cancer treatment
Post Holdings CEO returns after taking leave for cancer treatment


Dive Brief:

Dive Insight:

While Post has a deep executive bench and an organizational structure that likely allowed it to operate uninterrupted with Vitale out, the CPG company is undoubtedly stronger with its top executive back at the helm.

Vitale has developed a reputation as a strategic thinker and a prudent allocator of capital. He also is known to get deeply involved in deal making on a granular level and be reachable to top Post executives at night or during the weekend.

Post Holdings' CEO Rob Vitale

Optional Caption

Retrieved from Post Holdings.

 

For a company that has been active in M&A for much of its time as a public company, having Vitale is hugely important not only for his understanding of Post and the industry but his connections with bankers on Wall Street.

To be sure, Vitale didn’t fully step away from the business during his medical treatment. He told analysts late last year that he had been joining Post calls and would continue to participate in the company’s business as much as he could. 

“I am grateful to my family, my excellent medical team, my colleagues at Post, and all who have supported me,” Vitale said in a statement announcing his return from medical leave. “I am excited and energized about what we will accomplish in 2024 and beyond.”

Before Vitale’s medical leave, Post was divided into five segments that operated independently, with the leaders overseeing them reporting to the CEO. The structure remained in place while Vitale was away.

Post also has benefited from the fact that many of the company’s top executives, including Zadoks, have been with the business for years and were intimately familiar with its operations and strategy.

Post sales have risen from $4.6 billion in 2015, its first full fiscal year with Vitale at the helm, to about $6 billion in 2022 — a figure that excludes about $2 billion from businesses that have been divested or separately capitalized. 

Related posts

Stop & Shop recalls cantaloupe related to Salmonella outbreak

newsconquest

FDA’s traceability rule is a game changer for food safety

newsconquest

Beyond Meat refutes claims of unsanitary conditions at Pennsylvania plant

newsconquest